PHILADELPHIA — The associations of breast cancer recurrence scores (RS) with mortality measured using Oncotype DX, a commercial diagnostic...
PHILADELPHIA — Almost 40 percent of patients with metastatic melanoma harboring BRAF V600E mutations who were treated with a...
PHILADELPHIA – ADCT-402, an investigational antibody-drug conjugate, showed signs of clinical activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma,...
PHILADELPHIA — The American Association for Cancer Research (AACR), the world’s first and largest cancer research organization dedicated to...
The project will further enhance a unique, real-world clinico-genomic dataset through the joint efforts of nine biopharmaceutical companies PHILADELPHIA...
SAN ANTONIO — The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
BOSTON – The investigational farnesyl transferase inhibitor tipifarnib yielded durable objective responses in patients with recurrent and metastatic head...
BOSTON The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and...
BOSTON – The investigational MEK inhibitor selumetinib showed clinical responses in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas,...
BOSTON – Cyclin-dependent kinase (CDK) inhibitors, including palbociclib, were effective against patient-derived xenograft (PDX) mouse models of different tumor...